Access brought to you by: LOCKSS

Hepatology Clinical Trials

Terlipressin and Albumin Combination Therapy Improves Renal Function in HRS-1
Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial
HCV—Infected Patients with Compensated Cirrhosis Benefit from 12-Week, Once-Daily, Oral Combination of LDV and SOF
High Efficacy Rates with Grazoprevir Plus Elbasvir in HCV Monoinfection and HCV/HIV Coinfection
Interferon- and RBV-Free Treatment with LDV and SOF is Efficacious in Patients Coinfected with HCV and HIV
Rapid Sustained HCV Viral Load Reductions Achieved with ACH-3102 Plus SOF
SOF Plus GS-5816 Effective in Noncirrhotic Patients Infected with HCV GT-3: ELECTRON-2 Final Results
SOF Plus GS-5816 Effective in Noncirrhotic, Treatment-Naïve Patients Infected with HCV Genotypes 1 to 6